Latest Retro Biosciences News & Updates

See the latest news and media coverage for Retro. We track all announcements, press releases, and industry mentions in real time, all in one place.

Retro Biosciences (Retro)

Biotechnology company developing therapies targeting aging biology

retro.bio

Headquarters: Redwood City, United States
Company type: Private company
Number of employees: 100–200
Industry: Biotechnology & Medical Research

Last updated October 8

Latest news about Retro Biosciences (Retro)

In short: Retro reached first-in-human milestones, closed financing at a $1.8B valuation, and formed key partnerships with OpenAI, MCRI, and Multiply Labs.

Company announcements

May 22 Retro

Retro announces initial close of financing

The round values the company at $1.8 billion, led by 4P Capital, funding RTR242's clinical advancement and expansion of cell therapy, AI protein engineering, and manufacturing capabilities.

December 29, 2025 Retro

Retro achieves First In Human milestone

Retro becomes a clinical stage company after reaching the clinic in Q4. The organization thanks teams and anticipates 2026.

August 22, 2025 Retro

Retro Bio highlights collaboration with OpenAI on GPT-4b

The partnership focuses on using GPT-4b to engineer proteins that enhance stem cell reprogramming and accelerate their mission.

May 20, 2025 Retro

Retro Bio announces collaboration with MCRI

The partnership aims to develop preventative medicine by rejuvenating the blood system using a person's genetics to extend healthy lifespan by 10 years.

Media coverage

October 8 Yahoo

Silicon Valley billionaires are obsessed with reprogramming their bodies for longevity. The first human trial suggests they may be onto something.

The first humans are trying out cellular reprogramming for longevity. It looks like it might be...

September 11 Longevity Technology

Retro Biosciences tweaks its Alzheimer’s pill dosing

Sam Altman-backed Retro Biosciences is widening its Alzheimer’s trial after early doses showed no red flags. Most drug trials ...

August 26 MSN

Sam Altman's longevity company is testing an extra-strength Alzheimer's drug after disappointing trial results

The Sam Altman-backed longevity biotech company is upping the dose of its experimental Alzheimer's drug in clinical trials.

June 3 MSN

Can AI stop humans from ageing? Sam Altman is betting millions on it

A fresh debate around AI, healthcare and the future of human ageing has exploded online after a viral X post by Ricardo, a private content...

Never miss news about Retro

Track Retro and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Retro competitors & trending companies

Browse news for competitors to Retro and other trending companies.